[
  {
    "ts": null,
    "headline": "Gilead Sciences Unit Says Followup Data Support 'Durable' Efficacy of Tecartus CAR T-Cell Therapy",
    "summary": "Gilead Sciences' (GILD) Kite unit said Monday that long-term data from four analyses underpin the \"d",
    "url": "https://finnhub.io/api/news?id=21a6c46f1446a82e6b0f0f7ea296a1cd5d2337cf7c5e8c4e469ebc7aa7f2344b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733785068,
      "headline": "Gilead Sciences Unit Says Followup Data Support 'Durable' Efficacy of Tecartus CAR T-Cell Therapy",
      "id": 131898144,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences' (GILD) Kite unit said Monday that long-term data from four analyses underpin the \"d",
      "url": "https://finnhub.io/api/news?id=21a6c46f1446a82e6b0f0f7ea296a1cd5d2337cf7c5e8c4e469ebc7aa7f2344b"
    }
  },
  {
    "ts": null,
    "headline": "Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024",
    "summary": "SANTA MONICA, Calif., December 09, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) in patients with relapsed/refractory non-Hodgkin lymphomas (NHL) including follicular lymphoma (FL) or marginal zone lymphoma (MZL). The analysis demonstrated that after a median follow-up of more than five years, patients treated with Yescarta continued to experience durable response and long",
    "url": "https://finnhub.io/api/news?id=29ee0c41f3a396331f982056c56a8a476a076937779afd1b118e68caea2bd975",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733784300,
      "headline": "Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024",
      "id": 131898145,
      "image": "https://s.yimg.com/ny/api/res/1.2/.bhSbwYOeSqmastPp1gb8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zNjE-/https://media.zenfs.com/en/business-wire.com/7cbd0a95708c813fa6b7eb3c2887f99a",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "SANTA MONICA, Calif., December 09, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) in patients with relapsed/refractory non-Hodgkin lymphomas (NHL) including follicular lymphoma (FL) or marginal zone lymphoma (MZL). The analysis demonstrated that after a median follow-up of more than five years, patients treated with Yescarta continued to experience durable response and long",
      "url": "https://finnhub.io/api/news?id=29ee0c41f3a396331f982056c56a8a476a076937779afd1b118e68caea2bd975"
    }
  },
  {
    "ts": null,
    "headline": "Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits",
    "summary": "SANTA MONICA, Calif., December 09, 2024--Kite, a Gilead Company (Nasdaq: GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucabtagene autoleucel) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.",
    "url": "https://finnhub.io/api/news?id=790d5f943c863b3eb4d6a33d075a224171a15a804ad4effccbf09a4f3635ddaa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733779800,
      "headline": "Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits",
      "id": 131879608,
      "image": "https://s.yimg.com/ny/api/res/1.2/WBR_8egTD0t8DQpMyjbx0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zNjE-/https://media.zenfs.com/en/business-wire.com/2ca0a0475617783d9c88977ef644bcb3",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "SANTA MONICA, Calif., December 09, 2024--Kite, a Gilead Company (Nasdaq: GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucabtagene autoleucel) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.",
      "url": "https://finnhub.io/api/news?id=790d5f943c863b3eb4d6a33d075a224171a15a804ad4effccbf09a4f3635ddaa"
    }
  },
  {
    "ts": null,
    "headline": "Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.",
    "summary": "Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.",
    "url": "https://finnhub.io/api/news?id=67e4b587085932d0da27c0935c5158be47a17c8801999b47fbcd7b915e621473",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733759435,
      "headline": "Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.",
      "id": 131870703,
      "image": "https://media.zenfs.com/en/ibd.com/ca99382a9495e01f5703b092aadd1604",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.",
      "url": "https://finnhub.io/api/news?id=67e4b587085932d0da27c0935c5158be47a17c8801999b47fbcd7b915e621473"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL).",
    "url": "https://finnhub.io/api/news?id=09fff222caed8ca9822231b9c36870ad1aab37e77fe8976c65f39e541e4ab1c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733775300,
      "headline": "Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences",
      "id": 131879613,
      "image": "https://media.zenfs.com/en/zacks.com/00f1f0c06254fc058ca373b7d8f260e5",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL).",
      "url": "https://finnhub.io/api/news?id=09fff222caed8ca9822231b9c36870ad1aab37e77fe8976c65f39e541e4ab1c4"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=152b3bd4470973bbc3a8fbe28ab5b62218fa58f15fd2127296c1d45c12ea3925",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733762520,
      "headline": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
      "id": 131936579,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=152b3bd4470973bbc3a8fbe28ab5b62218fa58f15fd2127296c1d45c12ea3925"
    }
  }
]